The Advisory Council on the Misuse of Drugs (ACMD) is conducting a comprehensive review of the 2018 changes to cannabis medicines regulations in the UK. This review will directly shape how CBPMs are regulated, prescribed, and accessed for years to come. The consultation runs until 17 October 2025, 11:59 PM. This briefing provides guidance to […]
Read More
Nominations are now open for the Cannabis Industry Awards 2025, recognising individuals who have made outstanding contributions to the UK’s cannabis sector. The event is kindly presented by Curaleaf Laboratories and EastCann. The awards, hosted by the Cannabis Industry Council, Drug Science, and the Medical Cannabis Clinicians Society, will celebrate excellence across six categories, Winners will […]
Read More
Curaleaf Laboratories and EastCann present the Cannabis Industry Awards 2025, hosted by the Cannabis Industry Council, Drug Science, and the Medical Cannabis Clinicians Society. Together, we are proud to announce the return of the prestigious event, taking place on Thursday, 6 November 2025, at the historic Honourable Artillery Company, Armoury House, City Road, London EC1Y […]
Read More
The Government has stated that “there are no current plans” for electronic prescribing to be enabled for CBPMs from private clinics. In a response to a written question in Parliament, Health Minister Karin Smyth MP stated: “Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. Electronic prescribing […]
Read More
The Care Quality Commission (CQC) has published a report entitled ‘The safer management of controlled drugs: Annual update 2024’. This contains a section on CBPMs. CQC note that prescriptions of unlicensed CBPMs in independent services has increased by 130% between 31 March 2023 and 31 March 2024: 1 April 2022 to 31 March 2023: 150,527 […]
Read More
The Government has recently written to the ACMD about part 2 of their ‘barriers to research’ work, with some notable developments: General: “A new cross-government officials working group will focus on any new issues involving research with controlled drugs while also monitoring the changes following your recommendations.” Recommendation 1: Research using Schedule 1 Controlled Drugs […]
Read More
The CIC has produced an Impact Report to assess the organisation’s progress over the past two years. The report largely covers the period under former Co-Chairs Dr Callie Seaman and Jamie Bartley. Read now
Read More
The Food Standards Agency (FSA) has announced some updates in their approach to the consumer CBD industry. The key developments are as follows: The FSA continue to maintain that 10mg per day is the Acceptable Daily Intake (ADI), with some exceptions. The evidence behind this position remains unpublished. The FSA have established a ‘safe upper […]
Read More
In this month’s episode, Luke speaks to Nicole Farah, Founder and MD of Americana Communications. Nicole explores the role of effective PR in shaping the narrative surrounding cannabis and influencing legislation. Throughout she unpacks the differences that define discourse and policy on both sides of the Atlantic. The podcast can be listened to now via […]
Read More
CIC CEO Mike Morgan-Giles was a guest on the Institute of Economic Affairs (IEA) podcast this week, discussing cannabis policy and much more with host Reem Ibrahim. Mike discussed the CIC’s position on cannabis matters, as well as some wider thoughts on policy in general. Watch/listen now:
Read More